Supplementary material

Manuscript ID: d5848caa-ff3c-4797-8b50-c68dd376dacb

Development of water-soluble nanoformulations of novel pyrazolone derivatives and the evaluation of their antibacterial and antioxidant activities

Nkeiruka N. Igbokwe[1,5]; Eman I. Abdallah[1,6]; Vincent A. Obakachi[2]; Aviwe Ntsethe[3]; Mlindeli Gamede[4]; Rajshekhar Karpoormath[2]; Mbuso A. Faya[1]*

[1]Department of Pharmaceutics, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa
[2]Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa
[2]School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa
[4]Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
[5]Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Maiduguri, Borno State, Nigeria
[6]Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Wad Medani, Sudan

Results for HPLC Method validation

Table SM1: Summary of optimum system conditions for analysis

Parameter	Observed
Mobile Phase	ACN: Water (0.1% TFA)
Flow Rate	1 mL/min for Compound I and 0.5 mL/min for compound II
Column type	Shim-pack GIST C18 5 μm, 4.61.D × 150 mm
Injection volume	20 μL
Column Temperature	25 ℃
Retention Time	< 10 min

a. Linearity



Fig. SM1 Compound I calibration curve



Fig. SM2 Compound II calibration curve

b. Specificity and Suitability



Fig. SM3 Chromatograms of the Blank formulation [A], Methanol: solvent for dilution [B], the compound-loaded Nanosuspension [C], and Bare compound [D], which further established the specificity of the method and its suitable application in detecting the compound in nanosuspensions